Table 3.
Prevalence ratios (95% CI) for the presence of coronary atherosclerosis per one SD increment in GlycA levels; the MACS-CVD2 study*,†, ‡,§,‖
| Whole cohort (935) | HIV-infected (589) | HIV-uninfected (346) | |
|---|---|---|---|
| Coronary artery calcium | |||
| Model 1 | 1.12 (1.07 – 1.18) | 1.10 (1.04 – 1.17) | 1.18 (1.07 – 1.30) |
| Model 2 | 1.09 (1.03 – 1.15) | 1.08 (1.01 – 1.15) | 1.11 (1.00 – 1.22) |
| Model 3 | 1.09 (1.03 – 1.16) | 1.08 (1.01 – 1.16) | 1.13 (1.00 – 1.28) |
| Model 4 | 1.09 (1.03 – 1.15) | 1.07 (1.00 – 1.15) | 1.14 (1.01 – 1.28) |
| Model 5 | - | 1.07 (0.99 – 1.15) | - |
| p-for-interaction=0.11 | |||
| Coronary stenosis | |||
| Model 1 | 1.33 (1.13 – 1.56) | 1.28 (1.06 – 1.54) | 1.41 (1.04 – 1.93) |
| Model 2 | 1.20 (1.02 – 1.41) | 1.18 (0.97 – 1.45) | 1.26 (0.93 – 1.71) |
| Model 3 | 1.18 (1.00 – 1.39) | 1.12 (0.90 – 1.38) | 1.37 (1.02 – 1.84) |
| Model 4 | 1.15 (0.98 – 1.36) | 1.06 (0.86 – 1.32) | 1.53 (1.13 – 2.05) |
| Model 5 | - | 1.05 (0.83 – 1.31) | - |
| p-for-interaction=0.15 | |||
| Any plaque | |||
| Model 1 | 1.02 (0.98 – 1.07) | 1.01 (0.96 – 1.07) | 1.04 (0.97 – 1.11) |
| Model 2 | 1.00 (0.96 – 1.04) | 1.00 (0.95 – 1.05) | 1.00 (0.93 – 1.07) |
| Model 3 | 0.98 (0.94 – 1.03) | 0.97 (0.92 – 1.03) | 1.01 (0.94 – 1.10) |
| Model 4 | 0.98 (0.94 – 1.02) | 0.97 (0.92 – 1.02) | 1.01 (0.94 – 1.10) |
| Model 5 | - | 0.97 (0.92 – 1.03) | - |
| p-for-interaction=0.71 | |||
| Noncalcified plaque | |||
| Model 1 | 1.05 (0.99 – 1.12) | 1.05 (0.98 – 1.13) | 1.04 (0.93 – 1.18) |
| Model 2 | 1.03 (0.97 – 1.09) | 1.03 (0.96 – 1.11) | 1.00 (0.88 – 1.14) |
| Model 3 | 1.03 (0.96 – 1.10) | 1.04 (0.96 – 1.13) | 1.00 (0.87 – 1.14) |
| Model 4 | 1.02 (0.95 – 1.09) | 1.03 (0.95 – 1.12) | 1.00 (0.86 – 1.15) |
| Model 5 | - | 1.04 (0.96 – 1.13) | - |
| p-for-interaction=0.93 | |||
| Mixed plaque | |||
| Model 1 | 1.12 (1.01 – 1.24) | 1.11 (0.98 – 1.25) | 1.12 (0.94 – 1.34) |
| Model 2 | 1.05 (0.95 – 1.17) | 1.06 (0.93 – 1.21) | 1.07 (0.89 – 1.27) |
| Model 3 | 1.03 (0.92 – 1.15) | 1.01 (0.88 – 1.17) | 1.12 (0.93 – 1.35) |
| Model 4 | 1.02 (0.92 – 1.15) | 1.00 (0.86 – 1.15) | 1.12 (0.93 – 1.36) |
| Model 5 | - | 0.97 (0.83 – 1.13) | - |
| p-for-interaction=0.29 | |||
| Calcified plaque | |||
| Model 1 | 1.14 (1.04 – 1.26) | 1.10 (0.97 – 1.25) | 1.22 (1.05 – 1.42) |
| Model 2 | 1.12 (1.02 – 1.23) | 1.07 (0.94 – 1.22) | 1.19 (1.02 – 1.40) |
| Model 3 | 1.15 (1.04 – 1.27) | 1.11 (0.97 – 1.26) | 1.22 (1.03 – 1.46) |
| Model 4 | 1.15 (1.04 – 1.27) | 1.08 (0.95 – 1.24) | 1.22 (1.03 – 1.46) |
| Model 5 | - | 1.11 (0.96 – 1.28) | - |
| p-for-interaction=0.35 | |||
SD GlycA = 65.4 μmol/L
Prevalence ratios (95% CI) are from Poisson regression models that were progressively adjusted as follows:
Model 1: adjusted for age, race, scanning center, pre/post 2001-cohort, and HIV sero-status (in whole cohort analysis).
Model 2 (Main Model): Model 1 + systolic BP, BMI, physical activity level, use of hypertension medications, use of diabetes medications, fasting glucose, total and HDL cholesterol, use of lipid lowering medications, pack-years of tobacco smoking, eGFR and hepatitis C virus (HCV) - infection status.
Model 3: Model 2 + ln hsCRP, ln D-dimer, ln IL-6 and Fibrinogen.
Model 4: Model 3 + sCD163, sCD14, and ln CCL2.
Model 5: Model 4 + CD4 cell count, presence of detectable HIV RNA, nadir CD4 cell count, history of AIDS, duration of HAART, and use of protease inhibitors.
p-for-interaction adjusted for model 2
Bolded items are statistically significant (p≤0.05)